Minerva Neurosciences (NERV) Current Assets (2013 - 2026)
Minerva Neurosciences (NERV) posted Current Assets of $79.1 million for Q1 2026, down 4.8% on a QoQ basis from $83.1 million in Q4 2025, and up 341.32% year-over-year from $17.9 million in Q1 2025.
Minerva Neurosciences (NERV) Current Assets (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Current Assets history runs 14 years deep, the most recent figure standing at $79.1 million for Q1 2026.
- Quarterly Current Assets rose 341.32% year-over-year to $79.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.1 million (up 341.32% YoY) and the FY2025 annual result came in at $83.1 million, up 273.16% from the prior year.
- Current Assets was $79.1 million for Q1 2026 at Minerva Neurosciences, down from $83.1 million in the prior quarter.
- Across five years, Current Assets topped out at $83.1 million in Q4 2025 and bottomed at $13.0 million in Q3 2025.
- A 5-year average of $40.9 million and a median of $40.2 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets sank 53.39% — and 2026, when it jumped 341.32%.
- Minerva Neurosciences' Current Assets stood at $40.2 million in 2022, then climbed by 4.59% to $42.0 million in 2023, then plunged by 46.98% to $22.3 million in 2024, then surged by 273.16% to $83.1 million in 2025, then declined by 4.8% to $79.1 million in 2026.
- Business Quant data shows NERV's Current Assets at $79.1 million in Q1 2026, $83.1 million in Q4 2025, and $13.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 289.93 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | 73.04 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 3.59 Mn |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 6.60 Bn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 11.73 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 18.21 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | 521.86 Mn |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 8.07 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Minerva Neurosciences | 183.94 Mn | 183.94 Mn | - | 79.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.11 Mn |
| Dec 31, 2025 | 83.10 Mn |
| Sep 30, 2025 | 13.02 Mn |
| Jun 30, 2025 | 15.55 Mn |
| Mar 31, 2025 | 17.92 Mn |
| Dec 31, 2024 | 22.27 Mn |
| Sep 30, 2024 | 27.94 Mn |
| Jun 30, 2024 | 31.41 Mn |
| Mar 31, 2024 | 35.62 Mn |
| Dec 31, 2023 | 42.00 Mn |
| Sep 30, 2023 | 48.23 Mn |
| Jun 30, 2023 | 52.23 Mn |
| Mar 31, 2023 | 36.67 Mn |
| Dec 31, 2022 | 40.16 Mn |
| Sep 30, 2022 | 44.84 Mn |
| Jun 30, 2022 | 50.04 Mn |
| Mar 31, 2022 | 55.70 Mn |
| Dec 31, 2021 | 62.20 Mn |
| Sep 30, 2021 | 67.44 Mn |
| Jun 30, 2021 | 75.23 Mn |